FDA orders a blindness risk warning on weight loss drugs including Ozempic and Wegovy
Summary
Companies making popular weight loss drugs, including Ozempic and Wegovy, will be required to add a warning label about a rare eye condition that can cause blindness, the US Food and Drug Administration (FDA) has said, Sky News reported on Tuesday 10 November. The Independent reported that weight loss drugs were linked to a new rare side effect as new warning labels are required, writing that nearly 30 million Americans are taking weight-loss drugs. On Wednesday 11 November The Independent headlined that the FDA is to require GLP-1 manufacturers to make a major change to warning labels.
Latest: The Independent headlined that the FDA is to require GLP-1 manufacturers to make a major change to warning labels.
Written automatically by an AI from the articles' headlines and descriptions. It can contain errors: follow the links to read the articles.
How it unfolded
Wednesday 11 November
The Independent headlined that the FDA is to require GLP-1 manufacturers to make a major change to warning labels.
- 03:31The Independent FDA to require GLP-1 manufacturers to make major change to warning labels
Tuesday 10 November
Companies making popular weight loss drugs, including Ozempic and Wegovy, will be required to add a warning label about a rare eye condition that can cause blindness, the US Food and Drug Administration has said, Sky News reported, and The Independent wrote that nearly 30 million Americans are taking weight-loss drugs.
- 09:25The Independent Weight loss drugs linked to new rare side effect as new warning labels required
Monday 9 November
- 19:24Sky News FDA orders blindness risk warning on weight loss drugs